Review clinical trials related to Patients With Advanced Solid Tumors. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.
A Phase I/II, Open-Label, Non-Randomized, Multi-Centre First-in-Human Study of CAN016 in Patients with Advanced Solid Tumors
Provide informed consent voluntarily [+9]
Patient has received any anticancer therapy (including chemotherapy, targeted th... [+5]
This study is a Phase I clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor efficacy of LNF2105 in patients with advanced solid tumors.
Male or female aged ≥18 years. [+4]
Prior treatment with an antibody-drug conjugate (ADC) exhibiting one of the foll... [+22]
The goals of this trial are to identify the dose limiting toxicities, to determine the maximum tolerated dose and the recommended dose of PM534 in patients with advanced solid tumors. All Patients will receive PM534 via intravenous.
Voluntarily signed and dated written informed consent, obtained prior to any spe... [+16]
History of long QT syndrome. [+23]
This is a 2-part, phase I/II, open-label, multicenter study designed to evaluate the safety, PK, PD and preliminary efficacy of TCC1727 tablets administered orally QD.
Male or female subjects who have provided voluntary informed consent for partici... [+18]
Imaging examination suggests intracranial metastasis, which requires local treat... [+20]
Based on the activation and regulation of immune system by cytokines, mRNA encoding cytokines has become one of the important directions of mRNA tumor drug development. This product (ABOD2011) is a new generation mRNA product for intratumoral injection. The primary objective of this study is to assess the safety and tolerability, of ABOD2011 in patients with advanced solid tumors that progressed after standard systemic therapy.
18 years and older. [+10]
Any systemic anti-tumor therapy, within 28 days prior to the first dose. [+10]